Imatinib and ruxolitinib association: first experience in two patients

Alessandra Iurlo(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Umberto Gianelli(University of Milan), Francesca Binda(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Cristina Bucelli(University of Milan), Elisa Santambrogio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Elisa Fermo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Daniele Cattaneo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Davide Rapezzi(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Haematologica
March 14, 2014
10.3324/haematol.2013.102525
Cited by 29

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272